CNSP (STOCKS)

    CNS Pharmaceuticals, Inc. Common Stock

    $5.040000
    -0.060000 (-1.18%)
    Prev close: $5.100000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Major
    CEO
    Rami Levin
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $7.53M
    Employees
    4
    P/E (TTM)
    -0.21
    P/B (TTM)
    57.50
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Mar 2026)
    Revenues $0.00
    Nonoperating Income/Loss $137.81K
    Operating Expenses $16.62M
    Research and Development $10.07M
    Other Operating Expenses $6.55M
    Operating Income/Loss -$16.62M
    Income/Loss From Continuing Operations After Tax -$16.49M
    Income/Loss From Continuing Operations Before Tax -$16.49M
    Net Income/Loss -$16.49M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$16.49M
    Net Income/Loss Available To Common Stockholders, Basic -$16.49M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$29.63
    Diluted Earnings Per Share -$29.63
    Basic Average Shares 1,661,988
    Diluted Average Shares 1,661,988
    Assets $4.65M
    Current Assets $4.08M
    Noncurrent Assets $574.85K
    Fixed Assets $22.01K
    Non-current Prepaid Expenses $552.84K
    Liabilities $4.58M
    Current Liabilities $4.58M
    Noncurrent Liabilities $0.00
    Equity $70.71K
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $70.71K
    Liabilities And Equity $4.65M
    Net Cash Flow From Operating Activities -$15.22M
    Net Cash Flow From Operating Activities, Continuing -$15.22M
    Net Cash Flow From Investing Activities $6.56M
    Net Cash Flow From Investing Activities, Continuing $6.56M
    Net Cash Flow From Financing Activities $5.15M
    Net Cash Flow From Financing Activities, Continuing $5.15M
    Net Cash Flow -$3.51M
    Net Cash Flow, Continuing -$3.51M
    Comprehensive Income/Loss -$16.49M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$16.49M
    Other Comprehensive Income/Loss $0.00